Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197697 | 0.79 | HTR2A (0.51) | HTR2AHTR2CKDM4EALDH1A1POLB | |
| SCHEMBL18527235 | 0.78 | HTR2A (0.56) | HTR2AHTR2CKDM4EALDH1A1KMT2A | |
| SCHEMBL18202354 | 0.77 | SIGMAR1 (0.42) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| SCHEMBL4048826 | 0.77 | HTR2A (0.62) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| SCHEMBL8133155 | 0.77 | MAPT (0.38) | HTR2AHTR2CKDM4EALDH1A1POLB | |
| SCHEMBL16197695 | 0.76 | HTR2A (0.48) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| SCHEMBL4049250 | 0.75 | HTR2A (0.59) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| SCHEMBL31487256 | 0.74 | HTR2A (0.51) | HTR2AHTR2CKDM4ETSHRMAPT | |
| SCHEMBL1520653 | 0.74 | HTR2A (0.51) | HTR2AHTR2CKDM4ETSHRMAPT | |
| SCHEMBL970777 | 0.73 | HTR2A (1.00) | HTR2AHTR2CKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009097515-A2 | [A]-FUSED INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097515-A2 | [A]-FUSED INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PIK3C2A | HTR2A 780/4885HTR2C 826/4885KDM4E 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.